Ciprolac 50 mg (ciprofloxacin) 40 tablets
Description
Ciprolac 50 mg tablets are flat-cylindrical with a line, white or almost white, weight 0.5 g
Storage
Ciprolac 50 mg 1 tablet contains the active substance: ciprofloxacin hydrochloride – 50 mg.
Pharmacological properties
ATCvet classification code: QJ01MA02. Antibacterial agents for systemic use, fluoroquinolone group, ciprofloxacin.
Ciprofloxacin is a synthetic antibacterial drug of the fluoroquinolone group with a broad spectrum of action.
The drug is active against gram-negative and gram-positive microorganisms, especially against E. coli, Salmonella spp., Shigella spp., Enterobacter spp., Enterobacter spp., Klebsiella spp., Proteus spp., Serratia spp., Camphylobacter spp., Pseudomonas aeruginosa, Yersin. spp., Aeromonas spp., Haemophilus spp., are also sensitive to the drug: Pasteurella multocida, Plesiomonas shigelloides, Campylobacter jejuni, Chlamydia trachomatis, Listeria monocytogenes, Corynebacterium diphtheriase, Streptococcus spp. (including penicillinase-producing and methicillin-resistant strains), Mycoplasma spp., Mycobacterium spp.
The mechanism of action of ciprofloxacin is the inhibition of bacterial DNA gyrase (topoisomerase II), which disrupts DNA replication and synthesis of bacterial cellular proteins, which leads to the death of the microorganism.
After ingestion, ciprofloxacin is easily absorbed in the gastrointestinal tract (mainly in the duodenum and colon) and distributed in organs and tissues of the body (excluding fat-rich tissues), enters the pleura, peritoneum, lymph, ocular fluid and placenta.
The maximum concentration of ciprofloxacin in blood serum is reached in 1,5-2 hours, therapeutic concentration remains within 24 hours after oral administration of drug.
Ciprofloxacin is excreted from the body mainly in unchanged form and partly in the form of metabolites in urine and bile, in lactating animals also with milk.
Tsiprolak by the degree of impact on the body refers to moderately dangerous substances (hazard class 3 according to GOST 12.1.007-76), in the recommended doses does not have a local irritant and resorptive-toxic effect, has no embryotoxic and teratogenic properties.
Application
For the treatment of dogs and cats with chronic and acute bacterial infections, the causative agents of which are sensitive to ciprofloxacin:
- respiratory infections
- infections of the gastrointestinal tract and biliary tract
- kidney and/or urinary tract infections
- genital infections
- skin and soft tissue infections
- bone and joint infections
- secondary infections in viral diseases.
Dosage
Tsiprolak tablets are administered to animals individually orally once a day for 3-5 days in a dose
Animal species | Dose of the drug | |
Ciprolac 15 mg | Ciprolac 50 mg | |
Cats, dogs of small breeds | 1 table for every 3 kg of body weight | – |
Dogs of medium and large breeds | – | 1 table for every 10 kg of body weight |
Side effect
Side effects and complications in dogs and cats when using the drug according to the instructions are usually not observed.
In case of increased individual sensitivity of the animal to fluoroquinolones and the appearance of signs of side effects (nausea, vomiting, diarrhea, dizziness, ataxia, sleep disturbances, convulsions, heart rhythm disorders, skin rashes, edema, tendinitis and arthropathy) use of the drug
Contraindication
Intense insolation should be avoided during treatment to prevent photosensitization. The use of the drug is not allowed: in severe disorders of cartilage; at the defeats of a nervous system which are followed by spasms; females during pregnancy and lactation, puppies and kittens until the end of the growth period.
Interaction with other medicinal products and other forms of interaction
Concomitant use of ciprofloxacin with theophylline, caffeine, indirect anticoagulants is accompanied by an increase in the concentration of these drugs in the blood. Antacids containing ions of aluminum and magnesium (maalox, aluminum hydroxide), sucralfate, preparations containing ions of calcium, iron, zinc, bismuth reduce the bioavailability of fluoroquinolones. Phenytoin increases the risk of seizures, especially in patients with epilepsy. Antagonism with nitrofurantoin, tetracycline, chloramphenicol is noted.
Release form
Blisters of 10 tablets, cardboard boxes of 2 blisters.
Storage
In the closed packaging of the manufacturer, separately from food and feed, in a dry place, protected from direct sunlight, out of reach of children at a temperature of 0 ° C to 25 ° C. Shelf life – 4 years.